BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). STUDY TYPE: Retrospective, multicenter. POPULATION: Three hundred and fifty-two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. FIELD STRENGTH/SEQUENCES: 1.5 T and 3.0 T/precontrast and postcontrast T1-weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2-weighted FSE and T2-FLAIR. ASSESSMENT: Images of patients with extra-axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR]; SI measurements at regions-of-interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of -0.4. STATISTICAL TESTS: Student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. RESULTS: The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above -0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. DATA CONCLUSION: 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3.

• Klíčová slova
• GBCA safety, comparative studies, contrast efficacy, gadobenate dimeglumine,
• MeSH
• diethylentriaminpentaacetát gadolinia MeSH
• kontrastní látky MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• meglumin analogy a deriváty   MeSH
• mozek diagnostické zobrazování   MeSH
• nádory mozku * MeSH
• organokovové sloučeniny * MeSH
• retrospektivní studie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• diethylentriaminpentaacetát gadolinia MeSH
• gadobenic acid MeSH Prohlížeč
• kontrastní látky MeSH
• meglumin MeSH
• organokovové sloučeniny * MeSH

BACKGROUND: The control of cutaneous leishmaniasis (CL) is facilitated by knowledge of factors associated with the treatment failures in endemic countries. The aim of this evaluation was to identify the potential risk determinants which might affect the significance of demographic and clinical characteristics for the patients with anthroponotic CL (ACL) and the outcome of meglumine antimoniate (MA) (Glucantime) treatment. METHODOLOGY/PRINCIPAL FINDINGS: This current was executed as a cohort spanning over a period of 5 years which centered in southeastern part of Iran. Altogether, 2,422 participants were evaluated and 1,391 eligible volunteer patients with ACL caused by Leishmania tropica were included. Overall, 1,116 (80.2%) patients received MA intraleisionally (IL), once a week for 12 weeks along with biweekly cryotherapy, while 275 (19.8%) patients received MA alone (20 mg/kg/day for 3 weeks) (intramuscular, IM). The treatment failure rate in ACL patients was 11% using IL combined with cryotherapy plus IM alone, whilst 9% and 18.5% by IL along with cryotherapy or IM alone, respectively. Multivariate logistic regression model predicted 5 major associated-risk determinants including male (odds ratio (OR) = 1.54, confidence interval (CI) = 1.079-2.22, p = 0.018), lesion on face (OR = 1.574, CI = 1.075-2.303, p = 0.02), multiple lesions (OR = 1.446, CI = 1.008-2.075, p = 0.045), poor treatment adherence (OR = 2.041, CI = 1.204-3.46, p = 0.008) and disease duration > 4 months (OR = 2.739, CI = 1.906-3.936, p≤0.001). CONCLUSIONS/SIGNIFICANCE: The present study is the original and largest cohort of ACL patients who treated with MA. A comprehensive intervention and coordinated action by the health authorities and policy-makers are crucial to make sure that patients strictly follow medical instructions. Early detection and effective therapy < 4 months following the onset of the lesion is critical for successful treatment of the patients. Since a significant number of patients are still refractory to MA, reducing man-vector exposure and development of new effective alternative drugs are essential measures against ACL due to L. tropica.

• MeSH
• antiprotozoální látky terapeutické užití   MeSH
• dítě MeSH
• dospělí MeSH
• kohortové studie MeSH
• kojenec MeSH
• kryoterapie metody   MeSH
• Leishmania tropica izolace a purifikace   MeSH
• leishmanióza kožní farmakoterapie   epidemiologie   mikrobiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• meglumin antimoniát terapeutické užití   MeSH
• mladiství MeSH
• mladý dospělý MeSH
• neúspěšná terapie MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• rizikové faktory MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• kojenec MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Írán epidemiologie   MeSH
• Názvy látek
• antiprotozoální látky MeSH
• meglumin antimoniát MeSH

Leishmaniasis is one of the most important parasitic diseases after malaria. The standard treatment of leishmaniasis includes pentavalent antimonials (SbV); however, these drugs are associated with serious adverse effects. There have been very few studies pertaining to their side effects and mechanism of action in the fetus. This investigation examines the effects of meglumine antimoniate (MA) on the survival rate, angiogenesis and cellular apoptosis in the human umbilical vein endothelial cells (HUVECs). HUVECs were treated with varying doses of MA (100-800 μg/ml) for 24, 48 and 72 h and the survival rate was studied by colorimetric assay, flow cytometry, immunocytochemistry, migration (scratch) assay and tube formation assay. The results of quantitative real-time PCR (qPCR) studies indicated that the most important genes involved in presenting angiogenesis included VEGF and its receptors (Kdr and Flt-1), NP1 and Hif-1α genes including the anti-apoptotic gene of Bcl2, were significantly reduced compared to the control group (p < 0.05). In contrast, the most leading genes involved in the phenomenon of apoptosis were P53, Bax, Bak, Apaf-1 and caspases 3, 8 and 9, which were significantly up regulated compared to the control group (p < 0.05).

• Klíčová slova
• Angiogenesis, Apoptosis, HUVECs, Meglumine antimoniate, Toxicity,
• MeSH
• antiprotozoální látky toxicita   MeSH
• apoptóza účinky léků   MeSH
• C-reaktivní protein genetika   MeSH
• endoteliální buňky pupečníkové žíly (lidské) účinky léků   fyziologie   MeSH
• faktor 1 indukovatelný hypoxií - podjednotka alfa genetika   MeSH
• fyziologická neovaskularizace účinky léků   MeSH
• kultivované buňky MeSH
• lidé MeSH
• meglumin antimoniát toxicita   MeSH
• nádorový supresorový protein p53 genetika   MeSH
• pohyb buněk účinky léků   MeSH
• proteiny nervové tkáně genetika   MeSH
• proteiny regulující apoptózu genetika   MeSH
• vaskulární endoteliální růstový faktor A genetika   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antiprotozoální látky MeSH
• C-reaktivní protein MeSH
• faktor 1 indukovatelný hypoxií - podjednotka alfa MeSH
• meglumin antimoniát MeSH
• nádorový supresorový protein p53 MeSH
• neuronal pentraxin MeSH Prohlížeč
• proteiny nervové tkáně MeSH
• proteiny regulující apoptózu MeSH
• vaskulární endoteliální růstový faktor A MeSH
• VEGFA protein, human MeSH Prohlížeč

Currently, there is no satisfactory treatment modality available for cutaneous leishmaniasis (CL). The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL). Twenty end-stage unresponsive patients with ACL were identified for participation in this single-group trial study. Simultaneously, each patient was received a combination of levamisole pills along with Glucantime during the remedy course. Several in vitro complementary experiments were performed to evaluate the mode of action of levamisole and Glucantime alone and in combination using a macrophage model, in vitro MTT assay, flow cytometry and quantitative real time PCR (qPCR). Overall, 75% of the patients showed complete clinical cure, 10% partially improved and the remaining (15%) had underlying chronic diseases demonstrated no response to the treatment regimen. In in vitro studies, there was no cytotoxic effect associated with these drugs in the range of our experiments. The findings by the flow cytometric analysis represented that the highest apoptotic values corresponded to the drugs combination (32.23%) at 200 μg/ml concentration. Finally, the gene expression level of IL-12 p40, iNOS and TNF-α promoted while the level of IL-10 and TGF-β genes reduced as anticipated. The findings clearly indicated that the combination of levamisole and Glucantime should be considered in end-stage unresponsive patients with ACL who have not responded to basic treatments. The immunomodulatory role of levamisole in mounting immune system as documented by the in vitro experiments and further substantiated by this single-group trail study was highlighted.

• Klíčová slova
• Cutaneous leishmaniasis, End-stage patients, Glucantime, Levamisole, Treatment,
• MeSH
• antiprotozoální látky farmakologie   terapeutické užití   MeSH
• buněčné linie účinky léků   MeSH
• chronická nemoc terapie   MeSH
• dítě MeSH
• dospělí MeSH
• fixní kombinace léků MeSH
• interleukin-10 metabolismus   MeSH
• interleukin-12 - podjednotka p40 metabolismus   MeSH
• kombinovaná farmakoterapie MeSH
• Leishmania tropica účinky léků   patogenita   MeSH
• leishmanióza kožní farmakoterapie   MeSH
• levamisol aplikace a dávkování   farmakologie   terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• makrofágy účinky léků   MeSH
• meglumin antimoniát aplikace a dávkování   farmakologie   terapeutické užití   MeSH
• mladiství MeSH
• mladý dospělý MeSH
• myši MeSH
• senioři MeSH
• synthasa oxidu dusnatého, typ II metabolismus   MeSH
• TNF-alfa metabolismus   MeSH
• transformující růstový faktor beta metabolismus   MeSH
• viabilita buněk účinky léků   MeSH
• výsledek terapie MeSH
• zvířata MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• myši MeSH
• senioři MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antiprotozoální látky MeSH
• fixní kombinace léků MeSH
• IL10 protein, human MeSH Prohlížeč
• interleukin-10 MeSH
• interleukin-12 - podjednotka p40 MeSH
• levamisol MeSH
• meglumin antimoniát MeSH
• NOS2 protein, human MeSH Prohlížeč
• synthasa oxidu dusnatého, typ II MeSH
• TNF-alfa MeSH
• transformující růstový faktor beta MeSH

BACKGROUND AND PURPOSE: Gadobenate dimeglumine (MultiHance) has higher r1 relaxivity than gadoterate meglumine (Dotarem) which may permit the use of lower doses for MR imaging applications. Our aim was to compare 0.1- and 0.05-mmol/kg body weight gadobenate with 0.1-mmol/kg body weight gadoterate for MR imaging assessment of brain tumors. MATERIALS AND METHODS: We performed crossover, intraindividual comparison of 0.1-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 1) and 0.05-mmol/kg gadobenate with 0.1-mmol/kg gadoterate (Arm 2). Adult patients with suspected or known brain tumors were randomized to Arm 1 (70 patients) or Arm 2 (107 patients) and underwent 2 identical examinations at 1.5 T. The agents were injected in randomized-sequence order, and the 2 examinations were separated by 2-14 days. MR imaging scanners, imaging sequences (T1-weighted spin-echo and T1-weighted high-resolution gradient-echo), and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images for diagnostic information (degree of definition of lesion extent, lesion border delineation, visualization of lesion internal morphology, contrast enhancement) and quantitatively for percentage lesion enhancement and lesion-to-background ratio. Safety assessments were performed. RESULTS: In Arm 1, a highly significant superiority (P < .002) of 0.1-mmol/kg gadobenate was demonstrated by all readers for all end points. In Arm 2, no significant differences (P > .1) were observed for any reader and any end point, with the exception of percentage enhancement for reader 2 (P < .05) in favor of 0.05-mmol/kg gadobenate. Study agent-related adverse events were reported by 2/169 (1.2%) patients after gadobenate and by 5/175 (2.9%) patients after gadoterate. CONCLUSIONS: Significantly superior morphologic information and contrast enhancement are demonstrated on brain MR imaging with 0.1-mmol/kg gadobenate compared with 0.1-mmol/kg gadoterate. No meaningful differences were recorded between 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate.

• MeSH
• dospělí MeSH
• klinické křížové studie MeSH
• kontrastní látky MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie metody   MeSH
• meglumin analogy a deriváty   MeSH
• nádory mozku patologie   MeSH
• organokovové sloučeniny MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• gadobenic acid MeSH Prohlížeč
• gadoterate meglumine MeSH Prohlížeč
• kontrastní látky MeSH
• meglumin MeSH
• organokovové sloučeniny MeSH

Leishmaniasis is an infectious disease caused by parasitic flagellates of the genus Leishmania. The authors present a case of 44-year-old man with Crohn's disease treated successfully with infliximab. This case report shows rare visceral leishmaniasis with cutaneous symptoms in an immunocompromised patient. Skin manifestations may occur before or after the visceral infection and they are often diverse.

• Klíčová slova
• immunosuppression, skin manifestation, visceral leishmaniasis,
• MeSH
• antiflogistika škodlivé účinky   MeSH
• antiprotozoální látky škodlivé účinky   MeSH
• Crohnova nemoc diagnóza   farmakoterapie   imunologie   MeSH
• dospělí MeSH
• fatální výsledek MeSH
• gastrointestinální látky škodlivé účinky   MeSH
• imunokompromitovaný pacient MeSH
• infliximab MeSH
• leishmanióza kožní chemicky indukované   diagnóza   farmakoterapie   imunologie   parazitologie   MeSH
• leishmanióza viscerální chemicky indukované   diagnóza   farmakoterapie   imunologie   parazitologie   MeSH
• lidé MeSH
• meglumin antimoniát MeSH
• meglumin škodlivé účinky   MeSH
• monoklonální protilátky škodlivé účinky   MeSH
• organokovové sloučeniny škodlivé účinky   MeSH
• srdeční arytmie chemicky indukované   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antiflogistika MeSH
• antiprotozoální látky MeSH
• gastrointestinální látky MeSH
• infliximab MeSH
• meglumin antimoniát MeSH
• meglumin MeSH
• monoklonální protilátky MeSH
• organokovové sloučeniny MeSH

BACKGROUND AND PURPOSE: Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors. MATERIALS AND METHODS: Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR. RESULTS: One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (κ = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers). CONCLUSIONS: Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose.

• MeSH
• dospělí MeSH
• kontrastní látky MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie metody   MeSH
• meglumin analogy a deriváty   MeSH
• mladý dospělý MeSH
• nádory mozku patologie   MeSH
• odchylka pozorovatele MeSH
• organokovové sloučeniny * MeSH
• reprodukovatelnost výsledků MeSH
• senioři MeSH
• senzitivita a specificita MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• gadobenic acid MeSH Prohlížeč
• gadobutrol MeSH Prohlížeč
• kontrastní látky MeSH
• meglumin MeSH
• organokovové sloučeniny * MeSH

AIM: To compare the quality of magnetic resonance angiographies (MRAs) performed with different contrast agents and to evaluate the effect of body mass index (BMI) and ejection fraction (EF) on the quality of these MRAs. MATERIALS AND METHODS: 120 patients between the age of 43 and 86 years were subjected to MRAs with different contrast agents (Gadobutrolum, Dimeglumini gadobenas, Gadofosveset trisodium). Each patient's BMI was calculated, and EF was established using MR examination of the heart. Objective evaluations of the quality of the MRAs were done using abdominal fat-to-aorta enhancement ratio (FAR) comparisons. This ratio was then correlated with the patient's BMI and EF. Subjective evaluations of the quality of the MRAs were done by 5 blinded evaluators. Correlation analysis and analysis of variance were used for statistical assessement. RESULTS: There was no statistically significant difference in FAR for any of the contrast agent groups. There was a mesoscale correlation between a patient's BMI and FAR. However, no correlation was found between the EF and FAR for any of the contrast agent groups. The results of the subjective evaluation showed that there was no statistical difference in the quality of MRAs regardless of the contrast agent used. CONCLUSION: Subjectively there was no statistically significant difference in the quality of the MRAs. Irrespective of the type of contrast used or the patient's EF, the lower the BMI of a patient the higher the signal enhancement and hence the better the quality of the MRA produced in that patient.

• MeSH
• aorta abdominalis patologie   MeSH
• bérec krevní zásobení   MeSH
• dospělí MeSH
• gadolinium * MeSH
• index tělesné hmotnosti * MeSH
• kontrastní látky * MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonance kinematografická * MeSH
• magnetická rezonanční angiografie * MeSH
• meglumin analogy a deriváty   MeSH
• onemocnění periferních arterií diagnóza   patofyziologie   MeSH
• organokovové sloučeniny * MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• srdce MeSH
• tepový objem * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• gadobenic acid MeSH Prohlížeč
• gadobutrol MeSH Prohlížeč
• gadofosveset trisodium MeSH Prohlížeč
• gadolinium * MeSH
• kontrastní látky * MeSH
• meglumin MeSH
• organokovové sloučeniny * MeSH

AIMS: In the present study we tested the efficacy of N-acetylcysteine (NAC) to minimize nephrotoxic effects of iodine contrast agents in intact rats as well as in 5/6-nephrectomized (5/6-Nx) rats. METHODS: Rats were allocated to a group of intact rats (n = 42) and a group of 5/6-Nx rats (n = 42). After 1 month of recovery from surgery, 5/6-Nx rats and intact (sham-operated) animals received either 6 ml/kg body weight (b.w.) meglumine ioxithalamate (Telebrix 350) or 6 ml/kg b.w. iohexol (Omnipaque 350) intravenously with or without pretreatment with 100 mg/kg b.w. NAC. Plasma and urinary concentrations of creatinine, sodium and protein in 24-hour urine collections were determined prior to and on days 1, 3 and 7 after drug administration. RESULTS: In intact animals, contrast agents caused no significant changes in kidney function throughout the duration of the experiment. In contrast, significant increases in plasma creatinine levels and decreases in creatinine clearance were induced by both contrast agents in 5/6-Nx rats. These changes were significantly attenuated by NAC pretreatment. CONCLUSION: The results of the present study demonstrate that iodine contrast agent-induced nephropathy in 5/6-Nx rats is significantly attenuated by intravenous pretreatment with NAC.

• MeSH
• acetylcystein aplikace a dávkování   farmakologie   MeSH
• jod škodlivé účinky   MeSH
• johexol škodlivé účinky   MeSH
• kontrastní látky škodlivé účinky   MeSH
• krysa rodu Rattus MeSH
• meglumin-jothalamát škodlivé účinky   MeSH
• nefrektomie MeSH
• nemoci ledvin chemicky indukované   prevence a kontrola   MeSH
• premedikace metody   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• acetylcystein MeSH
• jod MeSH
• johexol MeSH
• kontrastní látky MeSH
• meglumin-jothalamát MeSH
• meglumine ioxithalamate MeSH Prohlížeč

One of the recognised complications of catheter ablation is pulmonary venous stenosis. The aim of this study was to compare two methods of evaluation of pulmonary venous diameter for follow-up assessment of the above complication: (1) a linear approach evaluating two main diameters of the vein, (2) semiautomatically measured cross-sectional area (CSA). The study population consists of 29 patients. All subjects underwent contrast-enhanced magnetic resonance angiography (CeMRA) of the pulmonary veins (PVs) before and after the ablation; 14 patients were also scanned 3 months later. PV diameter was evaluated from two-dimensional multiplanar reconstructions by measuring either the linear diameter or CSA. A comparison between pulmonary venous CSA and linear measurements revealed a systematic difference in absolute values. This difference was not significant when comparing the relative change CSA and quadratic approximation using linear extents (linear approach). However, a trend towards over-estimation of calibre reduction was documented for the linear approach. Using CSA assessment, significant PV stenosis was found in ten PVs (8%) shortly after ablation. Less significant PV stenosis, ranging from 20 to 50% was documented in other 18 PVs (15%). CeMRA with CSA assessment of the PVs is suitable method for evaluation of PV diameters.

• MeSH
• dospělí MeSH
• fantomy radiodiagnostické MeSH
• fibrilace síní chirurgie   MeSH
• katetrizační ablace škodlivé účinky   MeSH
• kontrastní látky MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční angiografie metody   MeSH
• meglumin analogy a deriváty   MeSH
• organokovové sloučeniny MeSH
• počítačové zpracování obrazu MeSH
• reprodukovatelnost výsledků MeSH
• senioři MeSH
• stenóza pulmonální chlopně diagnóza   etiologie   MeSH
• studie případů a kontrol MeSH
• venae pulmonales * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• gadobenic acid MeSH Prohlížeč
• kontrastní látky MeSH
• meglumin MeSH
• organokovové sloučeniny MeSH